Exogenus Therapeutics
Cantanhede
About Exogenus Therapeutics
Exogenus Therapeutics is engineering cell biology for innovative therapeutic solutions. Exo-T is a biotechnology company dedicated to the pre-clinical and clinical development of innovative cellular-based therapies applied to regenerative medicine, specifically for the skin lesions treatment. The company is presently developing its first product, Exo-Wound, for the treatment of chronic wounds. The project that led to the creation of the company (Nanoinspire) participated in COHiTEC 2014 program and is the result of the research developed in collaboration with Crioestaminal SA, Biocant, and Centre for Neurosciences and Cellular Biology of Coimbra University.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $968.9K
- Funding stage: Private Equity
- Last round: Private Equity (Apr 2024)
- Website: exogenustherapeutics.com
- Phone: +351 231 419 040
Industries & Categories
Biotechnology, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/exogenus-therapeutics-2892 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.